As to the Patented Medicine Prices Review Board, yes, there is, as I understand it, ongoing review of that. Dealing with PMPRB, the pricing issues and so on was not part of the work of the vaccine task force; that did not enter into our discussions.
In terms of the advice that we gave and the negotiations between the government and the individual companies, any issues related to pricing and any authorizations under PMPRB would have been part of discussions between those two groups.